Volume 84, Issue 2_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Frequency and levels of IgG antibodies to an N-terminal fragment of the MSP-1 (200L) protein, in individuals naturally exposed to malaria in four endemic areas of Brazil, were evaluated by enzyme-linked immunosorbent assay. Plasma samples of 261 -infected individuals from communities of Macapá, Novo Repartimento, Porto Velho, and Plácido de Castro in the Amazonian region with different malaria transmission intensities. A high mean number of studied individuals (89.3%) presented with antibodies to the 200L that correlated with the number of previous malaria infections; there were significant differences in the frequency of the responders (71.9–98.7) and in the antibody levels (1:200–1:51,200) among the four study areas. Results of this study provide evidence that 200L is a naturally immunogenic fragment of the MSP-1 and is associated with the degree of exposure to parasites. The fine specificity of antibodies to 200L is currently being assessed.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Feachem RG, , The Malaria Elimination Group, 2009. Shrinking the Malaria Map: A guide on Malaria Elimination for Policy Makers. San Francisco, CA: The Global Health Group, University of California, 85. [Google Scholar]
  2. Mendis K, Sina BJ, Marchesini P, Carter R, , 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97106. [Google Scholar]
  3. Brazilian Health Ministry, 2007. Epidemiological survey of malaria in Brazil. Secretariade Vigilanciaem Saúde/Ministérioda Saúde, ed., Saúde, Brasil. [Google Scholar]
  4. WHO, 2008. World Malaria Report. Geneva, Switzerland. [Google Scholar]
  5. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD, , 2004. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71: 239247. [Google Scholar]
  6. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG, , 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum . PLoS ONE 3: e3571.[Crossref] [Google Scholar]
  7. Nogueira PA, Alves FP, Fernandez-Becerra C, Pein O, Santos NR, Pereira da Silva LH, Camargo EP, del Portillo HA, , 2006. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun 74: 27262733.[Crossref] [Google Scholar]
  8. O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, Marsh K, , 2008. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 79: 185191. [Google Scholar]
  9. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM, , 1997. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65: 16061614. [Google Scholar]
  10. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S, , 1992. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz 87 (Suppl 3): 3742.[Crossref] [Google Scholar]
  11. Holder AA, , 1988. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 41: 7297. [Google Scholar]
  12. McBride JS, Newbold CI, Anand R, , 1985. Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum . J Exp Med 161: 160180.[Crossref] [Google Scholar]
  13. Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, Kanbara H, Hattori T, Tanabe K, , 2002. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA 99: 1634816353.[Crossref] [Google Scholar]
  14. Tanabe K, Mackay M, Goman M, Scaife JG, , 1987. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum . J Mol Biol 195: 273287.[Crossref] [Google Scholar]
  15. Gentz R, Certa U, Takacs B, Matile H, Dobeli H, Pink R, Mackay M, Bone N, Scaife JG, , 1988. Major surface antigen p190 of Plasmodium falciparum: detection of common epitopes present in a variety of plasmodia isolates. EMBO J 7: 225230. [Google Scholar]
  16. Strych W, Miettinen-Baumann A, Lottspeich F, Heidrich HG, , 1987. Isolation and characterization of the 80,000 dalton Plasmodium falciparum merozoite surface antigen. Parasitol Res 73: 435441.[Crossref] [Google Scholar]
  17. Guttinger M, Romagnoli P, Vandel L, Meloen R, Takacs B, Pink JR, Sinigaglia F, , 1991. HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int Immunol 3: 899906.[Crossref] [Google Scholar]
  18. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, , 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820827.[Crossref] [Google Scholar]
  19. Herrera-Arévalo M, Rosero F, Herrera S, Caspers P, Rotmann D, Sinigaglia F, Certa U, , 1992. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun 60: 154158. [Google Scholar]
  20. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F, Arevalo-Herrera M, Herrera S, , 2005. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73: 1624. [Google Scholar]
  21. Mertens F, Levitus G, Camargo LM, Ferreira MU, Dutra AP, Del Portillo HA, , 1993. Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil. Am J Trop Med Hyg 49: 383392. [Google Scholar]
  22. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LHP, Camargo EP, , 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641648. [Google Scholar]
  23. Coura JR, Suarez-Mutis M, Ladeia-Andrade S, , 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection—a review. Mem Inst Oswaldo Cruz 101: 229237. [Google Scholar]
  24. Brazilian Ministry of Health, 2005. Malaria Diagnosis. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/manual_diag_malaria.pdf. Accessed October 25, 2006. [Google Scholar]
  25. Kimura M, Kneko O, Liu Q, Zhou M, Kawamoto F, Wataya Y, Otani S, Yamaguchi Y, Tanake K, , 1997. Identification of the four species of human malaria parasites by nested PCR that targets variant sequences in the small subunit rRNA gene. Parasitol Int 46: 9195.[Crossref] [Google Scholar]
  26. Herrera S, Gomez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Mendez F, Wang R, Chitnis CE, Yazdani SS, Arevalo-Herrera M, , 2005. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg 73: 4449. [Google Scholar]
  27. Barbedo MB, Ricci R, Jimenez MC, Cunha MG, Yazdani SS, Chitnis CE, Rodrigues MM, Soares IS, , 2007. Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax . Mem Inst Oswaldo Cruz 102: 335339.[Crossref] [Google Scholar]
  28. Soares IS, da Cunha MG, Silva MN, Souza JM, Del Portillo HA, Rodrigues MM, , 1999. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg 60: 357363. [Google Scholar]
  29. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW, , 2009. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malar J 8: 162.[Crossref] [Google Scholar]
  30. Pitabut N, Panichakorn J, Mahakunkijcharoen Y, Hirunpetcharat C, Looareesuwan S, Khusmith S, , 2007. IgG antibody profile to c-terminal region of Plasmodium vivax merozoite surface protein-1 in Thai individuals exposed to malaria. Southeast Asian J Trop Med Public Health 38: 17. [Google Scholar]
  31. Wickramarachchi T, Premaratne PH, Perera KL, Bandara S, Kocken CH, Thomas AW, Handunnetti SM, Udagama-Randeniya PV, , 2006. Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. Infect Immun 74: 798801.[Crossref] [Google Scholar]
  32. Zeyrek FY, Babaoglu A, Demirel S, Erdogan DD, Ak M, Korkmaz M, Coban C, , 2008. Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey. Am J Trop Med Hyg 78: 729732. [Google Scholar]
  33. Chappel JA, Holder AA, , 1993. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol 60: 303311.[Crossref] [Google Scholar]
  34. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA, , 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum . J Mol Biol 307: 13811394.[Crossref] [Google Scholar]
  35. Egan AF, Blackman MJ, Kaslow DC, , 2000. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 68: 14181427.[Crossref] [Google Scholar]
  36. Levitus G, Mertens F, Speranca MA, Camargo LM, Ferreira MU, del Portillo HA, , 1994. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax . Am J Trop Med Hyg 51: 6876. [Google Scholar]
  37. Murhandarwati EE, Wang L, Black CG, Nhan DH, Richie TL, Coppel RL, , 2009. Inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun 77: 45104517.[Crossref] [Google Scholar]
  38. Bastos MS, Silva-Nunes M, Malafronte RS, Hoffman EH, Wunderlich G, Moraes SL, Fereira UM, , 2007. Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in Rural Amazonians. Clin Vaccine Immunol 14: 12491259.[Crossref] [Google Scholar]
  39. Ceravolo IP, Bruna-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, Krettli AU, Adams JH, Carvalho LH, , 2005. Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. Am J Trop Med Hyg 72: 675681. [Google Scholar]
  40. Ceravolo IP, Sanchez BA, Sousa TN, Guerra BM, Soares IS, Braga EM, McHenry AM, Adams JH, Brito CF, Carvalho LH, , 2009. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol 156: 502510.[Crossref] [Google Scholar]
  41. Rodrigues MH, Rodrigues KM, Oliveira TR, Comodo AN, Rodrigues MM, Kocken CH, Thomas AW, Soares IS, , 2005. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 35: 185192.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 21 Jan 2010
  • Accepted : 19 Apr 2010
  • Published online : 04 Feb 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error